BioTech 365

JUNE 3, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bayer picks up radiotherapeutics biotech to prop up dwindling sales in prostate cancer program.Bayer picks up radiotherapeutics biotech to prop up dwindling sales in prostate cancer program … Continue reading →

Sales 40

Sales Research 40

Pharma Times

SEPTEMBER 26, 2023

EpiSwitch is designed for men with prostate cancer risk in the UK and is 94% accurate - News - PharmaTimes

131

131

BioTech 365

SEPTEMBER 16, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ESMO: Novartis links prostate cancer drug to improved pain, quality of life as regulatory filings near.ESMO: Novartis links prostate cancer drug to improved pain, quality of life … Continue reading →

Drugs 40

Drugs Research 40

BioTech 365

SEPTEMBER 21, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ESMO: Early days, but Amgen’s BiTE drug in prostate cancer shows encouraging activity.ESMO: Early days, but Amgen’s BiTE drug in prostate cancer shows encouraging activity badams Fri, … Continue reading → (..)

Drugs 40

Drugs Research 40

BioTech 365

JANUARY 15, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: How a gene linked to the circadian clock could point to new prostate cancer treatments.How a gene linked to the circadian clock could point to new prostate … Continue reading →

Gene 40

Gene Research 40

Drug Discovery World

NOVEMBER 29, 2022

England will become the first country in Europe to roll out darolutamide (Nubeqa) to patients whose prostate cancer has spread to other parts of the body. . The drug works by blocking androgen receptors in cancer cells, which in turn blocks the effect of testosterone that allows the cancer cells to survive and multiply.

Drugs 98

Drugs Hormones Manufacturing Research 98

XTalks

JUNE 6, 2023

Prostate cancer stands as the second leading cause of cancer death among American men. Its early detection enhances the likelihood of survival, and survival is greatly influenced by the type and localization of the cancer. Gauden, CEO of Blue Earth Diagnostics, in the company’s news release.

FDA Approval 96

FDA Approval Clinical Trials Clinical Trials Marketing 96

Scienmag

FEBRUARY 28, 2022

Imperial College Academic Health Science Centre News Release Under STRICT embargo until: Monday 28 February 2022 23.30 EST Ultrasound scan can diagnose prostate cancer An ultrasound scan can be used to detect cases of prostate cancer, according to new research.

Research 65

Research 65

Drug Discovery World

OCTOBER 20, 2023

News round-up for 16-20 October by DDW Digital Content Editor Diana Spencer. To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research opportunities and advances’, the news round-up this week highlights the latest developments in oncology drug discovery.

Drugs 59

Drugs Research Medicine Marketing 59

World of DTC Marketing

FEBRUARY 17, 2022

The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. cost approximately $156.2

Medicine 271

Medicine Drugs Research Marketing 271

Drug Discovery World

MARCH 24, 2023

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in blood cancers, which could have huge implications for cancer treatment.

Drugs 52

Drugs Hormones Trials Research 52

pharmaphorum

DECEMBER 5, 2022

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

FDA Approval 57

FDA Approval Medicine Trials Production 57

Drug Discovery World

DECEMBER 2, 2022

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer . The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have emphatically proven that prednisolone should not be prescribed for olfactory disorders. .

Drugs 52

Drugs Development Medicine Research 52

Drug Discovery World

JUNE 2, 2023

News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another busy week for cancer drug development news.

Drugs 52

Drugs HR Antibody Clinical Trials 52

Drug Discovery World

JANUARY 26, 2024

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal, pancreatic and lung cancer and leukaemia.

Drugs 52

Drugs Trials Research Development 52

Drug Discovery World

SEPTEMBER 9, 2022

News round-up for 5-9 September by DDW Digital Content Editor Diana Spencer. Cancer research has been making headlines over the last seven days in the build-up to the European Society for Medical Oncology (ESMO) Congress 2022. This week’s top stories: Combination therapy halts lung cancer tumour growth in mice.

Drugs 52

Drugs Genetic Engineering Genetics Engineer 52

BioSpace

DECEMBER 27, 2020

Myovant Sciences’ stock rocketed 22% on news it was partnering with Pfizer to develop and commercialize relugolix for prostate cancer and women’s health.

Development 61

Development 61

The Pharma Data

NOVEMBER 20, 2020

Biopsy Reclassification Risk in Prostate Cancer Examined. 20, 2020 — Active surveillance for low-risk prostate cancer is associated with a low risk for cancer spread, according to a study published in the Dec. More News Resources. Professional. FRIDAY, Nov. 1 issue of The Journal of Urology.

HR 52

HR Genome Genomics Research 52

Drug Discovery World

MARCH 3, 2023

News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer. As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day , DDW has also reported on a number of developments in cancer drug discovery this week.

Drugs 52

Drugs Gene Expression Genome Genomics 52

Camargo

JULY 8, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Old Antidepressants Being Repurposed to Treat Cancer . In the News: June 2021 Regulatory and Development Updates.

Development 130

Development Bioequivalency Gene Expression Drugs 130

The Pharma Data

JANUARY 21, 2021

Mediterranean Diet Tied to Lower Risk for Prostate Cancer Progression. 21, 2021 — For men with newly diagnosed prostate cancer on active surveillance, adherence to the Mediterranean diet (MedD) is associated with a lower risk for Gleason grade group progression, according to a study published online Jan. Gregg, M.D.,

HR 52

HR Research 52

BioTech 365

DECEMBER 20, 2021

DGAP-News: MagForce AG / Key word(s): Study 20.12.2021 / 08:30 The issuer is solely responsible for the content of this announcement. Study for the Focal Ablation of Prostate Cancer with the … Continue reading → MagForce AG: Enrollment in Stage 2b of Pivotal U.S.

40

40

The Pharma Data

NOVEMBER 30, 2020

30, 2020 — Men with negative biopsies during active surveillance for low-risk prostate cancer are more likely to have good long-term outcomes, according to a study published online Nov. “These ‘hidden’ cancers have excellent long-term outcomes and remain ideal for continued active surveillance.”

Research 52

Research 52

Drug Discovery World

AUGUST 4, 2023

News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer. The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector.

Drugs 52

Drugs RNA Gene Scientist 52

The Pharma Data

APRIL 28, 2023

In August 2022, the FDA accepted the supplemental New Drug Application (sNDA) for Lynparza based on positive results from the pivotal PROpel trial, also published in NEJM Evidence. The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer.

HR 40

HR Trials Medicine Clinical Trials 40

The Pharma Data

DECEMBER 21, 2020

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer. 21, 2020 — Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. More News Resources. Professional. MONDAY, Dec. More Information. Source link.

Hormones 52

Hormones FDA Approval Trials Drugs 52

BioTech 365

JANUARY 12, 2021

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Study results/Miscellaneous 12.01.2021 / 09:48 The issuer is solely responsible for the content of this announcement. Seed implantation for prostate cancer is now to be … Continue reading → Berlin, 12 January 2021.

40

40

Drug Discovery World

JANUARY 23, 2024

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The positive news is there has been an increase in trial recruitment across all the top five indications in 2023. Read the full report.

Research 52

Research Clinical Trials Clinical Trials Trials 52

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 64

Development Research Drugs Antibody 64

The Pharma Data

JANUARY 12, 2021

Overall Cancer Death Rates Decreased From 1991 to 2018. 12, 2021 — Overall cancer death rates have decreased continuously from 1991 to 2018, according to a study published online Jan. 12 in CA: A Cancer Journal for Clinicians. million fewer cancer deaths. million fewer cancer deaths. Cancer Statistics, 2021.

Research 52

Research 52

The Pharma Data

JANUARY 27, 2021

27, 2021 — Aspirin use may improve survival for bladder and breast cancer , according to a study published online Jan. years) participating in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (1993 to 2001). However, there was no survival benefit with esophageal, gastric, pancreatic, or uterine cancer.

Trials 52

Trials Development Research 52

The Pharma Data

APRIL 28, 2023

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer RAHWAY, N.J.–(BUSINESS –(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S.

HR 40

HR FDA Approval Trials DNA 40

XTalks

NOVEMBER 30, 2023

Pfizer spinout SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has received US Food and Drug Administration (FDA) approval for the treatment of desmoid tumors, an ultra-rare subtype of non-cancerous soft tissue sarcomas that can cause severe pain and disfigurement.

FDA Approval 101

FDA Approval Trials Clinical Trials Clinical Trials 101

The Pharma Data

JANUARY 19, 2021

19, 2021 — During 1999 to 2018, there was a decrease in the rate of cancer-related suicide, according to a study published online Jan. 19 in the Journal of the National Cancer Institute. The largest decreases in cancer-related suicide rates were seen among high-risk populations, including male patients (AAPC, ?

Research 52

Research 52

Pharmaceutical Technology

OCTOBER 13, 2022

The news of the offer came just weeks after Myovant and its partner, Pfizer , received the US Food and Drug Administration's (FDA) expanded approval of Myfembree (estradiol + norethindrone acetate + relugolix) for the management of moderate to severe pain associated with endometriosis.

Hormones 130

Hormones FDA Approval Drugs Marketing 130

STAT News

DECEMBER 5, 2022

… Johnson & Johnson said it does not intend to make an offer for Horizon Therapeutics, days after the developer of medicines for rare autoimmune and inflammatory diseases revealed it was in talks with the company , Bloomberg News writes. regulatory approval, Bloomberg News says.  Pluvicto is already cleared in the U.S.

Insulin 52

Insulin Manufacturing Medicine Drugs 52